FDA reviewing "possible link" between Parkinson's drug Stalevo and prostate cancer risk
This article was originally published in Scrip
Executive Summary
The US FDA is conducting an "ongoing safety review" of clinical data to assess whether patients taking Orion/Novartis's Parkinson's disease treatment Stalevo (a combination formulation of carbidopa, levodopa and entacapone) are at an increased risk for developing prostate cancer.